Trial reportScientific reports2024
Dapagliflozin added to metformin reduces perirenal fat layer in type 2 diabetic patients with obesity.
Trial report in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Perirenal fat as a potential marker and therapeutic target for metabolic syndrome: insights from a multicenter randomized controlled trial.Frontiers in endocrinology · 2025Trial
- Depot-Specific Cardiorenal Adipose Remodeling with SGLT2i in Chronic Kidney Disease.Journal of clinical medicine · 2026Article
- Dapagliflozin induces renal lipidomic remodeling and systemic metabolic improvement.Biology direct · 2026Article
- Ultrasound and MRI abdominal fat distribution and its associations with metabolic conditions in adults with abdominal obesity.Diabetes, obesity & metabolism · 2026Article
- Effects of perirenal fat accumulation on cardiometabolic and renal functions and mineralocorticoid receptor activation in primary aldosteronism.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Targeting adipose remodeling: Synergistic mechanisms of drugs and adipose-derived stem cells in obese type 2 diabetes mellitus.World journal of stem cells · 2025Review
- Perirenal Fat in Disease Progression: From Inflammatory Mediator to Therapeutic Target.International journal of urology : official journal of the Japanese Urological Association · 2025Review
- Perirenal adipose tissue accumulation mediates the adverse impact of the atherogenic index of plasma on lower extremity peripheral arterial disease.Scientific reports · 2025Article
- Expert Consensus Statement on Simplified Glycemic Care in Patients With Type 2 Diabetes Mellitus.Cureus · 2025Review
- Ultrasound evaluation of epicardial fat andFrontiers in endocrinology · 2025Article
- Metformin Activation of Sirtuin 3 Signaling Regulates Mitochondrial Function Improves Diabetes-Associated Cognitive Impairment.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- SGLT2 inhibitors as metabolic modulators: beyond glycemic control in type 2 diabetes.Frontiers in endocrinology · 2025Review
- Review
- The association of perirenal adipose tissue accumulation with left ventricular hypertrophy and the mediating role of insulin resistance: a cross-sectional study involving 1112 individuals with type 2 diabetes mellitus.Frontiers in endocrinology · 2024Article
- Perirenal fat thickness contributes to the estimated 10-year risk of cardiovascular disease and atherosclerotic cardiovascular disease in type 2 diabetes mellitus.Frontiers in endocrinology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Sodium-glucose co-transporters type 2 inhibitors (SLGT2i) are highly effective in controlling type 2 diabetes, but reported beneficial cardiovascular effects suggest broader actions on insulin resistance. Weight loss may be initially explained by glycosuria-induced net caloric output and secondary volumetric reduction, but its maintenance could be due to loss of visceral fat mass. Structured ultrasound (US) imaging of abdominal adipose tissue ("eco-obesity") is a recently described methodology used to measure 5 consecutive layers of abdominal fat, not assessable by DEXA or CT scan: superficial subcutaneous (SS), deep subcutaneous (DS), preperitoneal (PP), omental (Om) and right perirenal (RK). PP, Om and RK are predictors of metabolic syndrome (MS) with defined cut-off points. To assess the effect of SLGT2i on every fat depot we enrolled 29 patients with type 2 Diabetes (HbA1c 6.5-9%) and Obesity (IMC > 30 kg/m
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.